WE ARE SO EXCITED TO ANNOUNCE THE NEWS!
Our Ground-Breaking Study on the Gupta Program Published In The Prestigious Journal of Clinical Medicine
Giving Hope To Millions of Fibromyalgia Sufferers, as the First Randomized Controlled Trial Ever Published on a Neuroplasticity Program!
It is estimated that at least 2% to 5% of the population suffer from this complex pain condition in some form, and until now there has been a lack of effective treatments. The novel Neuroplasticity program known as “Amygdala and Insula Retraining” was combined with Mindfulness to create 'MAIR', also known as the Gupta Program, and was tested for 8 weeks against a control group engaging in an equivalent amount of relaxation techniques.
The results found that after just an 8 week intervention, the MAIR group had significantly greater reductions in symptoms and pain, and increases in overall health, compared to the control group:
Fibromyalgia & Its Impact
It is believed that around 10m people in the USA, and 2m people in the UK, may suffer from Fibromyalgia. It is a disabling syndrome of unknown cause, mainly characterized by widespread musculoskeletal pain and symptoms such as fatigue, stiffness, sleep problems, cognitive dysfunction, and distress. It generates a huge amount of suffering in the population, and a great economic burden for public health.
Here Are The Details of Our Study
This study was a randomized controlled trial (RCT), with a total of 41 Fibromyalgia patients who were randomized into two study arms: the active intervention group using a combination of Amygdala and Insula Retraining and Mindfulness (MAIR), and an active control group engaging in an equivalent amount of time in relaxation techniques (RT), both as add-ons to treatment as usual.
The MAIR group demonstrated significantly greater reductions in functional impairment, anxiety, and depression, as well as significant decreases in pain catastrophizing, with large effect sizes. There were also significant improvements in clinical severity and health-related quality of life, with large effect sizes.
The study also analysed changes in a brain chemical known as brain-derived neurotrophic factor (BDNF). Some studies have found this to be elevated in Fibromyalgia, with some authors suggesting its potential implication in worsening pain symptoms, as it plays a key role in a variety of neuroplasticity processes, including pain modulation, pain transduction, nociception, and hyperalgesia.
In the study, there were no changes in the BDNF levels in patients in the control group. However, in the active MAIR group, levels of BDNF were significantly reduced and approached those of pain-free controls, pointing towards a normalizing effect of MAIR.
About Ashok Gupta and The Gupta Program
For over two decades, the Gupta Program has been supporting patients with chronic conditions such as ME/CFS, Fibromyalgia, Chemical & Mold Sensitivities and post-viral fatigue to rebalance their nervous and immune systems using the principles of neuroplasticity and holistic health practises.
Ashok's Amygdala and insula hypothesis for chronic conditions, as published in 2001 in the medical journal “Medical Hypotheses”, indicates that conditions such as ME/CFS, Fibromyalgia, post-viral fatigue, and post-COVID syndrome, may be neurological in nature, caused by abnormalities in the functioning of various brain structures. Even once the original illness has been fought off, the immune and nervous systems may have become traumatised and stuck in a hyper-response mode. The brain and the body fall into this vicious cycle that perpetuates neurological and immune over-stimulation, physiological dysfunction, and many physical symptoms.
The revolutionary neuroplasticity and holistic health tools and techniques within the Gupta Program stop the amygdala and insula’s hyper-reactions, allowing the body to trigger the parasympathetic system, encouraging its own healing mechanisms to fully restore balance and homeostasis and enter its optimal healing state.